Cipla Medpro in agreement with Serum Institute India

To provide vaccines in South Africa

Cipla’s South African subsidiary Cipla Medpro has entered into an exclusive agreement with Serum Institute of India (SII) in South Africa. The partnership will enable affordable and accessible vaccines for South Africans, and also facilitate a reliable supply stream to the South African Government.

Paul Miller, Chief Executive Officer, Cipla Medpro, South Africa said, “This agreement will enable Cipla Medpro to become a significant player in the market. With a presence in 140 countries and 1.3 billion doses manufactured and sold, SII is an ideal ally for Cipla Medpro and this partnership will be instrumental in addressing the national vaccine shortage.”

SII manufactures a variety of vaccine classes including vaccines for polio, diphtheria, tetanus, BCG (Tuberculosis), Hepatitis B, measles, mumps and rubella. South Africa will be participating in the majority of these portfolios.

Michel Baijot, Head of Vaccines, Cipla said, “This Cipla Medpro – SII agreement reflects again the complementarities of our two like-minded companies in bringing high quality, affordable vaccines to more countries.”

The agreement stipulates that Cipla Medpro will become the holder of all Medical Control Council (MCC) regulatory approvals such as product registrations and marketing authorisations. Cipla Medpro has exclusivity and first right of refusal of the SII pipeline within South Africa.

Adar Poonawalla, Chief Executive Officer and Executive Director, SII said, “SII is looking to extend the strong partnership it has with Cipla in Europe and India by working with Cipla Medpro in South Africa.”

We are confident that this agreement will support the Department of Health in rolling out its expanded immunisation programme. Cipla Medpro will continuously look to partner with organisations that are aligned with the company’s ethos of advancing healthcare for all,” concludes Miller.

CiplaCipla MedproSerum Institute of Indiavaccine